Skip to main content
SpringerLink
Log in

Botresorptieremmers en preventie van osteonecrose van de kaak

  • Chapter
  • First Online:
Het tandheelkundig Jaar 2018

  • 281 Accesses

Samenvatting

Botresorptieremmers hebben een bewezen klinisch nut bij het voorkomen van complicaties bij osteoporose of bij patiënten met kanker en uitzaaiingen in het bot. Nieuwe inzichten in de pathofysiologie van deze aandoeningen hebben geleid tot het ontwikkelen van steeds krachtigere botresorptieremmers. Hoewel deze nieuwe middelen over het algemeen goed worden verdragen, is het gebruik ervan gekoppeld aan een klein risico voor het optreden van osteonecrose van de kaak (ONJ). Deze aandoening kan echter grote invloed hebben op de levenskwaliteit van de getroffen patiënten en bij ontbreken van goede behandelingsopties blijft preventie van essentieel belang. De tandarts vervult dan ook een cruciale rol in ONJ-preventie door het vermijden van invasieve tandheelkundige ingrepen (zoals extracties) bij risicopatiënten en het uitvoeren van een screenend tandheelkundig onderzoek. In dit hoofdstuk wordt een praktische benadering van de ONJ-problematiek en preventie uitgewerkt die bruikbaar is in de dagelijkse praktijk.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 119.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Literatuur

  • Black DM, Reid IR, Cauley JA, Cosman F, Leung PC, Lakatos P, Lippuner K, Cummings SR, Hue TF, Mukhopadhyay A, Tan M, Aftring RP, Eastell R. The effect of 6 versus 9 years of zoledronic acid treatment in osteoporosis: a randomized second extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res. 2015;30:934–44.

    Article  PubMed  Google Scholar 

  • Bone HG, Chapurlat R, Brandi ML, Brown JP, Czerwinski E, Krieg MA, Mellstrom D, Radominski SC, Reginster JY, Resch H, Ivorra JA, Roux C, Vittinghoff E, Daizadeh NS, Wang A, Bradley MN, Franchimont N. The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: results from the FREEDOM extension. J Clin Endocrinol Metab. 2013;98:4483–92.

    Article  PubMed  PubMed Central  Google Scholar 

  • Fleisch H. Development of bisphosphonates. Breast Cancer Res. 2002;4:30–4.

    Article  PubMed  Google Scholar 

  • Hoff AO, Toth BB, Altundag K, Johnson MM, Warneke CL, Hu M, Nooka A, Sayegh G, Guarneri V, Desrouleaux K, Cui J, Adamus A, Gagel RF, Hortobagyi GN. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res. 2008;23:826–36.

    Article  PubMed  Google Scholar 

  • Jansma J, Vissink A, Spijkervet FK, Roodenburg JL, Panders AK, Vermey A, Szabo BG, Gravenmade EJ. Protocol for the prevention and treatment of oral sequelae resulting from head and neck radiation therapy. Cancer. 1992;70:2171–80.

    Article  PubMed  Google Scholar 

  • Khan AA, Morrison A, Hanley DA, Felsenberg D, McCauley LK, O’Ryan F, Reid IR, Ruggiero SL, Taguchi A, Tetradis S, Watts NB, Brandi ML, Peters E, Guise T, Eastell R, Cheung AM, Morin SN, Masri BC. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res. 2015;30:3–23.

    Article  PubMed  Google Scholar 

  • Lacey DL, Boyle WJ, Simonet WS, Kostenuik PJ, Dougall WC, Sullivan JK, San Martin J, Dansey R. Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab. Nat Rev Drug Discov. 2012;11:401–19.

    Article  PubMed  Google Scholar 

  • Lipton A, Fizazi K, Stopeck AT, Henry DH, Brown JE, Yardley DA, Richardson GE, Siena S, Maroto P, Clemens M, Bilynskyy B, Charu V, Beuzeboc P, Rader M, Viniegra M, Saad F, Ke C, Braun A, Jun S. Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer. 2012;48:3082–92.

    Article  PubMed  Google Scholar 

  • Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 2003;61:1115–7.

    Article  PubMed  Google Scholar 

  • Migliorati CA, Casiglia J, Epstein J, Jacobsen PL, Siegel MA, Woo SB. Managing the care of patients with bisphosphonate-associated osteonecrosis: an american academy of oral medicine position paper. J Am Dent Assoc. 2005;136:1658–68.

    Article  PubMed  Google Scholar 

  • Morgan GJ, Davies FE, Gregory WM, Cocks K, Bell SE, Szubert AJ, Navarro-Coy N, Drayson MT, Owen RG, Feyler S, Ashcroft AJ, Ross F, Byrne J, Roddie H, Rudin C, Cook G, Jackson GH, Child JA. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet. 2010;376:1989–99.

    Article  PubMed  Google Scholar 

  • Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, O’Ryan F. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw – 2014 update. J Oral Maxillofac Surg. 2014;72:1938–56.

    Google Scholar 

  • Saad F, Brown JE,Poznak C van, Ibrahim T, Stemmer SM, Stopeck AT, Diel IJ, Takahashi S, Shore N, Henry DH, Barrios CH, Facon T, Senecal F, Fizazi K, Zhou L, Daniels A, Carriere P, Dansey R. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol. 2012;23:1341–7.

    Google Scholar 

  • Stopeck AT, Fizazi K, Body JJ, Brown JE, Carducci M, Diel I, Fujiwara Y, Martin M, Paterson A, Tonkin K, Shore N, Sieber P, Kueppers F, Karsh L, Yardley D, Wang H, Maniar T, Arellano J, Braun A. Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer. Support Care Cancer. 2016;24:447–55.

    Google Scholar 

  • Wyngaert T van den, Claeys T, Huizing MT, Vermorken JB, Fossion E. Initial experience with conservative treatment in cancer patients with osteonecrosis of the jaw (ONJ) and predictors of outcome. Ann Oncol. 2009;20:331–6.

    Google Scholar 

  • Wyngaert T van den, Huizing MT, Vermorken JB. Osteonecrosis of the jaw related to the use of bisphosphonates. Curr Opin Oncol. 2007;19:315–22.

    Google Scholar 

  • Wyngaert T van den, Lenssen O, Huizing MT. Prevention of osteonecrosis of the jaw (ONJ) in cancer patients receiving bisphosphonates: empty promise or effective strategy? A systematic review and meta-analysis. IBMS BoneKEY. 2012;9:S26.

    Google Scholar 

  • Walter C, Al-Nawas B, Wolff T, Schiegnitz E, Grotz KA. Dental implants in patients treated with antiresorptive medication – a systematic literature review. Int J Implant Dent. 2016;2:9.

    Article  PubMed  PubMed Central  Google Scholar 

  • Weilbaecher KN, Guise TA, McCauley LK. Cancer to bone: a fatal attraction. Nat Rev Cancer. 2011;11(6):411–25.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Nucleaire Geneeskunde, Universitair Ziekenhuis Antwerpen/Faculteit Geneeskunde en Gezondheidswetenschappen, Universiteit Antwerpen, Antwerpen, Nederland

    T. Van den Wyngaert MD, PhD (Senior staflid)

  2. Stomatologie-Maxillofaciale chirurgie, ZNA Middelheim, Antwerpen, Nederland

    O. Lenssen MD, FEBOMFS (Maxillofaciaal chirurg)

Authors
  1. T. Van den Wyngaert MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. O. Lenssen MD, FEBOMFS
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. University of Washington , SEATTLE, Washington, USA

    J.K.M. Aps

  2. Heerenveen, Friesland, The Netherlands

    S.C. Boxum

  3. Gent, Belgium

    M.A.A. De Bruyne

  4. Department Beeldvorming & Pathologie - F, KU Leuven - OMFS-IMPATH Onderzoeksgroep Department Beeldvorming & Pathologie - F, Leuven, Belgium

    R. Jacobs

  5. Praktijk voor Endodontologie , Zwolle, The Netherlands

    W.J. van der Meer

  6. afdeling Mondziekten, Radboud UMC afdeling Mondziekten, Nijmegen, The Netherlands

    M.E.L. Nienhuijs

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Bohn Stafleu van Loghum, onderdeel van Springer Media B.V.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Van den Wyngaert, T., Lenssen, O. (2018). Botresorptieremmers en preventie van osteonecrose van de kaak. In: Aps, J., Boxum, S., De Bruyne, M., Jacobs, R., van der Meer, W., Nienhuijs, M. (eds) Het tandheelkundig Jaar 2018. Bohn Stafleu van Loghum, Houten. https://doi.org/10.1007/978-90-368-1784-4_12

Download citation

  • DOI: https://doi.org/10.1007/978-90-368-1784-4_12

  • Published:

  • Publisher Name: Bohn Stafleu van Loghum, Houten

  • Print ISBN: 978-90-368-1783-7

  • Online ISBN: 978-90-368-1784-4

  • eBook Packages: Dutch language eBook collection

Publish with us

Policies and ethics

Search

Navigation